Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Myriad Genetics (MYGN): Biggest Revenue Beat In 2yrs - Jefferies
February 8, 2017 7:34 AM ESTJefferies analyst, Brandon Couillard, reiterated his Hold rating on shares of Myriad Genetics (NASDAQ: MYGN) even though MYGN posted its biggest revenue beat in >2 yrs. The analyst higlighted the evidence of stability in its flagship hereditary cancer (HC) unit, which grew sequentially (+3%), reversing... More
Ladenburg Thalmann Upgrades Myriad Genetics (MYGN) to Neutral
February 8, 2017 6:42 AM ESTLadenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $15.40 yesterday.
... MoreMyriad Genetics (MYGN) Tops Q2 EPS by 2c
February 7, 2017 4:28 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of... More
